A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 320 participants.
Also called NCT07716618
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 320 participants
- Registry
-
NCT07716618
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07716618. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-17 (actual); primary completion 2026-05-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- SAL0120 1mg
- Intervention (Drug)
- SAL0120 2mg
- Intervention (Drug)
- SAL0120 4mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Collaborator
- Salubris (Suzhou) Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07716618- Content hash
51b24dbbaaf6ae6db4a8bf3745bb810dcd76492e9d8e5b68ba7c2b860cc4829c